Accessibility Menu
ImpediMed logo

ImpediMed(ASX) IPD

Market CapA$18.31MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2007)-99%
5 Year-95%
1 Year-88%
1 Month+0%
A$0.01
+20.00%
+0.00Today
ImpediMed last closing stock price
MetricPriceDate
Last closeAUD 0.012026-08-13
ImpediMed stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-16.67%AUD 0.012026-08-06
1 month+0%AUD 0.012026-07-14
3 month-37.5%AUD 0.012026-05-15
Year to date-85.29%AUD 0.032025-12-31
1 year-88.1%AUD 0.042025-08-13
3 year-97.56%AUD 0.212023-08-14
5 year-95.24%AUD 0.112021-08-13
Since inception-99.34%AUD 0.762007-10-24

ImpediMed Financials at a Glance

Market Cap

A$18.31MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$25.78M

Net Income (TTM)

-A$45.59M

EPS (TTM)

-A$0.01

P/E Ratio

-0.42

Dividend

A$0.00

Beta (Volatility)

0.28 (Low)

Price

A$0.01

Volume

874,482

Open

A$0.01

Previous Close

A$0.01

Daily Range

A$0.01 - A$0.01

52-Week Range

A$0.00 - A$0.06

Estimated Earnings Date

Aug 27, 2026

IPD News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About ImpediMed

ImpediMed Limited is a medical software technology provider specializing in bioimpedance spectroscopy (BIS) instruments and software solutions. The company serves markets in Australia, North America, and internationally, focusing on non-invasive devices for evaluating lymphedema and monitoring fluid levels in heart failure patients.

Products and Services
  • SOZO: A non-invasive BIS device for lymphedema evaluation
  • SFB7: A single-channel BIS instrument for body composition analysis
  • ImpediVET: A BIS device designed for veterinary applications
Growth Outlook
  • Recent quarterly revenue increased to AUD 7.52 million, showing market demand
  • Strong cash position with AUD 18.85 million in cash and equivalents
  • Expansion into international markets is anticipated to drive future growth
Financial Highlights
  • Trailing twelve-month revenue of AUD 25.5 million indicates steady performance
  • Current ratio of 3.74 suggests strong liquidity and financial health
  • Net income for the latest quarter was AUD -12.28 million, reflecting ongoing investment
ImpediMed Limited is positioned in the healthcare sector, focusing on innovative medical devices that address critical health issues. The company's flagship product, SOZO, is gaining traction in the market, particularly for its applications in managing lymphedema and heart failure. The recent increase in quarterly revenue highlights the growing acceptance of these technologies. With a solid cash position, ImpediMed is well-equipped to invest in research and development, further enhancing its product offerings. The company's focus on expanding into international markets presents additional growth opportunities, potentially increasing its market share and revenue streams. Financially, while the company has reported net losses, the strong liquidity ratios indicate a robust financial foundation. This positions ImpediMed to navigate challenges while pursuing growth initiatives. Overall, the combination of innovative products, a strong cash position, and a focus on market expansion makes ImpediMed Limited an intriguing option for investors interested in the medical devices sector.
AI Generated • Jul 22, 2026

Industry

Healthcare Equipment and Supplies

Employees

77

CEO

Parmjot Bains, PhD

Headquarters

Carlsbad, CA 92008, US

IPD Financials

Key Financial Metrics (TTM)

Gross Margin

-5.85%

Operating Margin

-156.48%

Net Income Margin

-171.25%

Return on Equity

-165.13%

Return on Capital

-69.26%

Return on Assets

-63.53%

Earnings Yield

-2.38%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$18.31MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

3.66B

Volume

874.48K

Avg. Volume

7.66M

Financials (TTM)

Gross Profit

A$9.31M

Operating Income

-A$23.32M

EBITDA

-A$34.42M

Operating Cash Flow

-A$35.74M

Capital Expenditure

A$8.01M

Free Cash Flow

-A$27.73M

Cash & ST Invst.

A$18.85M

Total Debt

A$21.93M

ImpediMed Performance Analysis

ImpediMed annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30AUD 10,566,000N/A
20232023-06-30AUD 11,344,0007.4%
20242024-06-30AUD 10,319,000-9.0%
20252025-06-30AUD 12,724,00023.3%
ImpediMed sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-3015.7%
Q22024-12-318.5%
Q42025-06-3011.8%
Q22025-12-3111.9%
ImpediMed annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30AUD -0.01N/A
20232023-06-30AUD -0.01-3.4%
20242024-06-30AUD -0.01-14.0%
20252025-06-30AUD -0.0117.3%
ImpediMed sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-30N/A
Q22024-12-31-12.2%
Q42025-06-30-9.1%
Q22025-12-31N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

A$7.52M

+57.1%

Gross Profit

-A$6.52M

+16.8%

Gross Margin

-86.70%

N/A

Market Cap

A$18.31MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$237.82K

N/A

Employees

77

N/A

Net Income

-A$12.28M

-26.4%

EBITDA

-A$7.51M

+16.8%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

A$18.85M

-48.9%

Total Debt

A$21.93M

+1623.0%

Accounts Receivable

A$3.76M

+41.1%

Inventory

A$2.27M

+152.2%

Long Term Debt

A$21.63M

+2146.2%

Short Term Debt

A$303.00K

-2.3%

Return on Assets

-63.53%

N/A

Return on Invested Capital

-70.68%

N/A

Free Cash Flow

A$0.00

+100.0%

Operating Cash Flow

-A$9.50M

-40.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PCK.AXPainChek Limited
A$0.10+1.01%
MX1.AXMicro-X Limited
A$0.03-3.45%
GSS.AXGenetic Signatures Limited
A$0.06-1.72%
EYE.AXNova Eye Medical Limited
A$0.15-3.23%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$8.91-0.09%
SMCISuper Micro Computer
$39.16+0.04%
SPCXSpace Exploration Technologies
$141.29-0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.64+0.07%

Questions About IPD

What is the current price of ImpediMed?

ImpediMed is trading at A$0.01 per share.

What is the 52-week range for ImpediMed?

Over the past 52 weeks, ImpediMed has traded between A$0.00 and A$0.06.

How much debt does ImpediMed have?

As of the most recent reporting period, ImpediMed reported total debt of A$14.49M.

How much cash does ImpediMed have on hand?

ImpediMed reported A$22.18M in cash and cash equivalents in its most recent financial results.

What is ImpediMed’s dividend yield?

ImpediMed does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.